Overcoming disease-induced growth factor resistance in therapeutic angiogenesis using recombinant co-receptors delivered by a liposomal system

Biomaterials

Volumn 35, Issue 1, 2014, Pages 196-205

  Das, Subhamoy ^a   Singh, Gunjan ^a   Baker, Aaron B ^a  

^a The University of Texas at Austin   (United States)

Author keywords

Angiogenesis; Fibroblast growth factor 2 (FGF 2); Ischemia; Neovascularization; Peripheral arterial disease; Syndecan 4 proteoliposomes

Indexed keywords

ANGIOGENESIS; FIBROBLAST GROWTH FACTOR-2; ISCHEMIA; NEO-VASCULARIZATION; PERIPHERAL ARTERIAL DISEASE; PROTEOLIPOSOMES;

BLOOD VESSELS; DISEASES; MAMMALS; NUTRITION; PATIENT TREATMENT; SIGNALING;

DISEASE CONTROL;

ALGINIC ACID; FIBROBLAST GROWTH FACTOR 2; GROWTH FACTOR; HEPARANASE; NEUROPILIN 1; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEOLIPOSOME; RECOMBINANT PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; RECOMBINANT PROTEIN; RECOMBINANT SYNDECAN 1; RECOMBINANT SYNDECAN 4; SYNDECAN 1; SYNDECAN 4; UNCLASSIFIED DRUG; VASCULOTROPIN A;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL; CONTROLLED STUDY; DIABETES MELLITUS; INTRACELLULAR SIGNALING; LIPID DIET; LIPOSOMAL DELIVERY; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; SKELETAL MUSCLE;

MUS;

ANGIOGENESIS; FIBROBLAST GROWTH FACTOR-2 (FGF-2); ISCHEMIA; NEOVASCULARIZATION; PERIPHERAL ARTERIAL DISEASE; SYNDECAN-4 PROTEOLIPOSOMES;

ANIMALS; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; GROWTH SUBSTANCES; LIPOSOMES; MICE; MICE, INBRED C57BL; MUSCLE, SKELETAL; NEOVASCULARIZATION, PHYSIOLOGIC; RECEPTORS, CELL SURFACE; RECOMBINANT PROTEINS;

EID: 84887019141     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.09.105     Document Type: Article

References (48)

1. Shammas N.W. Epidemiology, classification, and modifiable risk factors of peripheral arterial disease. Vasc Health Risk Manag 2007, 3:229-234.
2. Hooi J.D., Kester A.D., Stoffers H.E., Overdijk M.M., van Ree J.W., Knottnerus J.A. Incidence of and risk factors for asymptomatic peripheral arterial occlusive disease: a longitudinal study. Am J Epidemiol 2001, 153:666-672.
3. Pande R.L., Perlstein T.S., Beckman J.A., Creager M.A. Secondary prevention and mortality in peripheral artery disease: National Health and Nutrition Examination Study, 1999 to 2004. Circulation 2011, 124:17-23.
4. Kudagi V.S., White C.J. Endovascular stents: a review of their use in peripheral arterial disease. Am J Cardiovasc Drugs 2013, 13:199-212.
5. Annex B.H. Therapeutic angiogenesis for critical limb ischaemia. Nat Rev Cardiol 2013, 10:387-396.
6. Adams R.H., Alitalo K. Molecular regulation of angiogenesis and lymphangiogenesis. Nat Rev Mol Cell Biol 2007, 8:464-478.
7. Ornitz D.M. FGFs, heparan sulfate and FGFRs: complex interactions essential for development. Bioessays 2000, 22:108-112.
8. Ferrara N., Gerber H.P., LeCouter J. The biology of VEGF and its receptors. Nat Med 2003, 9:669-676.
9. Pellet-Many C., Frankel P., Jia H., Zachary I. Neuropilins: structure, function and role in disease. Biochem J 2008, 411:211-226.
10. Chen E., Hermanson S., Ekker S.C. Syndecan-2 is essential for angiogenic sprouting during zebrafish development. Blood 2004, 103:1710-1719.
11. Battegay E.J., Rupp J., Iruela-Arispe L., Sage E.H., Pech M. PDGF-BB modulates endothelial proliferation and angiogenesis invitro via PDGF beta-receptors. JCell Biol 1994, 125:917-928.
12. Heldin C.H., Westermark B. Mechanism of action and invivo role of platelet-derived growth factor. Physiol Rev 1999, 79:1283-1316.
13. Ball S.G., Bayley C., Shuttleworth C.A., Kielty C.M. Neuropilin-1 regulates platelet-derived growth factor receptor signalling in mesenchymal stem cells. Biochem J 2010, 427:29-40.
14. Pellet-Many C., Frankel P., Evans I.M., Herzog B., Junemann-Ramirez M., Zachary I.C. Neuropilin-1 mediates PDGF stimulation of vascular smooth muscle cell migration and signalling via p130Cas. Biochem J 2011, 435:609-618.
15. Kim J., Lee J.H., Park H.S., Hwang J., Han I.O., Bae Y.S., et al. Syndecan-4 regulates platelet-derived growth factor-mediated MAP kinase activation by altering intracellular reactive oxygen species. FEBS Lett 2008, 582:2725-2730.
16. Fukai N., Kenagy R.D., Chen L., Gao L., Daum G., Clowes A.W. Syndecan-1: an inhibitor of arterial smooth muscle cell growth and intimal hyperplasia. Arterioscler Thromb Vasc Biol 2009, 29:1356-1362.
17. Cao R., Brakenhielm E., Li X., Pietras K., Widenfalk J., Ostman A., et al. Angiogenesis stimulated by PDGF-CC, a novel member in the PDGF family, involves activation of PDGFR-alphaalpha and -alphabeta receptors. FASEB J 2002, 16:1575-1583.
18. Moriya J., Wu X., Zavala-Solorio J., Ross J., Liang X.H., Ferrara N. PDGF-C promotes revascularization in ischemic limbs of diabetic mice. JVasc Surg 2013.
19. Norgren L., Hiatt W.R., Dormandy J.A., Nehler M.R., Harris K.A., Fowkes F.G. Inter-society Consensus for the management of peripheral arterial disease (TASC II). JVasc Surg 2007, 45(Suppl S):S5-S67.
20. Tirziu D., Simons M. Angiogenesis in the human heart: gene and cell therapy. Angiogenesis 2005, 8:241-251.
21. Simons M., Annex B.H., Laham R.J., Kleiman N., Henry T., Dauerman H., et al. Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical trial. Circulation 2002, 105:788-793.
22. Henry T.D., Annex B.H., McKendall G.R., Azrin M.A., Lopez J.J., Giordano F.J., et al. The VIVA trial: vascular endothelial growth factor in ischemia for vascular angiogenesis. Circulation 2003, 107:1359-1365.
23. Lederman R.J., Mendelsohn F.O., Anderson R.D., Saucedo J.F., Tenaglia A.N., Hermiller J.B., et al. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial. Lancet 2002, 359:2053-2058.
24. Lederman R.J., Tenaglia A.N., Anderson R.D., Hermiller J.B., Rocha-Singh K., Mendelsohn F.O., et al. Design of the therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (TRAFFIC) trial. Am J Cardiol 2001, 88:192-195. A6-7.
25. Udelson J.E., Dilsizian V., Laham R.J., Chronos N., Vansant J., Blais M., et al. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 improves stress and rest myocardial perfusion abnormalities in patients with severe symptomatic chronic coronary artery disease. Circulation 2000, 102:1605-1610.
26. Rajagopalan S., Mohler E.R., Lederman R.J., Mendelsohn F.O., Saucedo J.F., Goldman C.K., et al. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation 2003, 108:1933-1938.
27. Grines C.L., Watkins M.W., Helmer G., Penny W., Brinker J., Marmur J.D., et al. Angiogenic Gene Therapy (AGENT) trial in patients with stable angina pectoris. Circulation 2002, 105:1291-1297.
28. Kusumanto Y.H., van Weel V., Mulder N.H., Smit A.J., van den Dungen J.J., Hooymans J.M., et al. Treatment with intramuscular vascular endothelial growth factor gene compared with placebo for patients with diabetes mellitus and critical limb ischemia: a double-blind randomized trial. Hum Gene Ther 2006, 17:683-691.
29. Comerota A.J., Throm R.C., Miller K.A., Henry T., Chronos N., Laird J., et al. Naked plasmid DNA encoding fibroblast growth factor type 1 for the treatment of end-stage unreconstructible lower extremity ischemia: preliminary results of a phase I trial. JVasc Surg 2002, 35:930-936.
30. Belch J., Hiatt W.R., Baumgartner I., Driver I.V., Nikol S., Norgren L., et al. Effect of fibroblast growth factor NV1FGF on amputation and death: a randomised placebo-controlled trial of gene therapy in critical limb ischaemia. Lancet 2011, 377:1929-1937.
31. Shigematsu H., Yasuda K., Iwai T., Sasajima T., Ishimaru S., Ohashi Y., et al. Randomized, double-blind, placebo-controlled clinical trial of hepatocyte growth factor plasmid for critical limb ischemia. Gene Ther 2010, 17:1152-1161.
32. Creager M.A., Olin J.W., Belch J.J., Moneta G.L., Henry T.D., Rajagopalan S., et al. Effect of hypoxia-inducible factor-1alpha gene therapy on walking performance in patients with intermittent claudication. Circulation 2011, 124:1765-1773.
33. Jang E., Albadawi H., Watkins M.T., Edelman E.R., Baker A.B. Syndecan-4 proteoliposomes enhance fibroblast growth factor-2 (FGF-2)-induced proliferation, migration, and neovascularization of ischemic muscle. Proc Natl Acad Sci U S A 2012, 109:1679-1684.
34. Ilan N., Elkin M., Vlodavsky I. Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis. Int J Biochem Cell Biol 2006, 38:2018-2039.
35. Adeghate E. Molecular and cellular basis of the aetiology and management of diabetic cardiomyopathy: a short review. Mol Cell Biochem 2004, 261:187-191.
36. Skilton M.R., Chin-Dusting J.P., Dart A.M., Brazionis L., Lantieri O., O'Dea K., et al. Metabolic health, obesity and 9-year incidence of peripheral arterial disease: the D.E.S.I.R. study. Atherosclerosis 2011, 216:471-476.
37. Muoio D.M., Newgard C.B. Mechanisms of disease: molecular and metabolic mechanisms of insulin resistance and beta-cell failure in type 2 diabetes. Nat Rev Mol Cell Biol 2008, 9:193-205.
38. Seitz O., Schurmann C., Hermes N., Muller E., Pfeilschifter J., Frank S., et al. Wound healing in mice with high-fat diet- or ob gene-induced diabetes-obesity syndromes: a comparative study. Exp Diabetes Res 2010, 2010:476969.
39. Bouhidel O., Pons S., Souktani R., Zini R., Berdeaux A., Ghaleh B. Myocardial ischemic postconditioning against ischemia-reperfusion is impaired in ob/ob mice. Am J Physiol Heart Circ Physiol 2008, 295:H1580-H1586.
40. Emanueli C., Caporali A., Krankel N., Cristofaro B., Van Linthout S., Madeddu P. Type-2 diabetic Lepr(db/db) mice show a defective microvascular phenotype under basal conditions and an impaired response to angiogenesis gene therapy in the setting of limb ischemia. Front Biosci 2007, 12:2003-2012.
41. Schiekofer S., Galasso G., Sato K., Kraus B.J., Walsh K. Impaired revascularization in a mouse model of type 2 diabetes is associated with dysregulation of a complex angiogenic-regulatory network. Arterioscler Thromb Vasc Biol 2005, 25:1603-1609.
42. Chen G., Wang D., Vikramadithyan R., Yagyu H., Saxena U., Pillarisetti S., et al. Inflammatory cytokines and fatty acids regulate endothelial cell heparanase expression. Biochemistry 2004, 43:4971-4977.
43. Baker A.B., Groothuis A., Jonas M., Ettenson D.S., Shazly T., Zcharia E., et al. Heparanase alters arterial structure, mechanics, and repair following endovascular stenting in mice. Circ Res 2009, 104:380-387.
44. Baker A.B., Gibson W.J., Kolachalama V.B., Golomb M., Indolfi L., Spruell C., et al. Heparanase regulates thrombosis in vascular injury and stent-induced flow disturbance. JAm Coll Cardiol 2012, 59:1551-1560.
45. Baker A.B., Chatzizisis Y.S., Beigel R., Jonas M., Stone B.V., Coskun A.U., et al. Regulation of heparanase expression in coronary artery disease in diabetic, hyperlipidemic swine. Atherosclerosis 2010, 213:436-442.
46. Elfenbein A., Lanahan A., Zhou T.X., Yamasaki A., Tkachenko E., Matsuda M., et al. Syndecan 4 regulates FGFR1 signaling in endothelial cells by directing macropinocytosis. Sci Signal 2012, 5:ra36.
47. Nunes S.S., Outeiro-Bernstein M.A., Juliano L., Vardiero F., Nader H.B., Woods A., et al. Syndecan-4 contributes to endothelial tubulogenesis through interactions with two motifs inside the pro-angiogenic N-terminal domain of thrombospondin-1. JCell Physiol 2008, 214:828-837.
48. Zhang Y., Li J., Partovian C., Sellke F.W., Simons M. Syndecan-4 modulates basic fibroblast growth factor 2 signaling invivo. Am J Physiol Heart Circ Physiol 2003, 284:H2078-H2082.